- Stephanie Stahl, Shalu Manchanda, and Notch Sigua wrote a Patient Education Handout for the ATS which was published in the Blue Journal in December
- The role of the urethral microbiome in idiopathic urethritis in men” NIAID 1 R01 AI116706-01A1Co-PIs David Nelson, Batteiger
- Dr. Rajiv Agarwal- R01 Entitled “ChLorthalidone in Chronic Kidney Disease (CLICK) Study”- $2.9M over 5 years- Started 12/15/15. This double-blind, two-center, placebo-controlled, randomized trial will test the hypothesis that chlorthalidone will improve BP among subjects with advanced CKD and poorly controlled hypertension. The results of this trial will allow the safe and effective use of chlorthalidone among people with CKD and hypertension.
- Dr. Pierre Dagher- new VA Merit- “Protective pathways in sepsis-induced renal injury”- Projected start in April 2016 Endotoxin preconditioning leading to tolerance is a natural model of protection against sepsis and sepsis-induced renal failure. This grant investigates the mechanisms involved in endotoxin tolerance in order to identify novel therapeutic strategies to prevent and treat the devastating consequences of sepsis.
- Dr. Ranjani Moorthi- New K23- “Longitudinal Assessment of Skeletal Muscle Physiology in Dialysis Patients”- $796,000 over 5 years- Started 8/1/15 Patients new to dialysis have poor muscle strength and mass. With normal aging there is loss of muscle and slower walking speed. Similarly, these changes are accelerated in dialysis patients. In this proposal we address whether the process of loss of skeletal muscle loss is due to decreased building of new muscle. We will also characterize dialysis patients that are at higher risk for muscle or function loss, so that therapies can be designed to reverse or block this process.
- Dr. Mike Eadon- New K08- “Acute inhibition of renal gene expression to prevent nephrotoxicity”- $670,000 over 5 years- Start date of 7/1/16 Acute kidney injury is a common unintended consequence of prescribed medications that causes marked increases in mortality, hospital stay, and medical expenditures. Drug-induced kidney toxicity not only contributes to acute kidney injury, but also results in discontinuation of or delay in treatment of malignancy and other life threatening conditions. This proposal aims to test whether siRNA gene expression knockdown can be used as a molecular therapeutic to prevent drug-induced acute kidney injury.
Please click here to submit additional kudos